Advertisement

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

Published:August 12, 2017DOI:https://doi.org/10.1016/j.jgo.2017.07.010

      Abstract

      Objectives

      Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age.

      Methods

      Efficacy and safety were analyzed by treatment arm and age (≥ or <65 years).

      Results

      Overall, 443 patients were ≥65 years old (205 in aflibercept arm; 238 in placebo arm) and 783 were <65 years old (407 in aflibercept arm; 376 in placebo arm). Median OS was 12.6 versus 11.3 months (hazard ratio [HR]: 0.85; 95.34% CI 0.68–1.07) in patients ≥65 years old and 14.5 versus 12.5 months (HR: 0.80; 95.34% CI 0.67–0.95) in those patients <65 years old, for patients receiving FOLFIRI plus aflibercept or placebo, respectively. There was no interaction between treatment and age. Treatment-emergent adverse events (AEs) were comparable for patients <65 years and ≥65 years old. The incidence of grade 3/4 AEs was higher for patients ≥65 years old than for those <65 years old in both the aflibercept (89.3% versus 80.5%) and placebo (67.4% versus 59.4%) arms. Interaction tests for grade 3/4 antiangiogenic agent-related AEs suggested no heterogeneity between the older and younger patient populations (p > 0.1).

      Conclusion

      A limited but consistent benefit on both OS and PFS was associated with the addition of aflibercept to FOLFIRI compared with placebo in patients <65 and ≥65 years old, with a marked but manageable increase in the toxicity profile in older patients.

      Trial Registration

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ervik M.
        • Lam F.
        • Ferlay J.
        • Mery L.
        • Soerjomataram I.
        • Bray F.
        Cancer today.
        International Agency for Research on Cancer, Lyon, France2016 (Available from:)
        http://gco.iarc.fr/today
        Date accessed: September 5, 2016
        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • Eser S.
        • Mathers C.
        • Rebelo M.
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int J Cancer. 2015; 136: E359-86
        • Howlader N.
        • Noone A.M.
        • Krapcho M.
        • Miller A.P.
        • Bishop K.
        • Altekruse S.F.
        • et al.
        SEER cancer statistics review, 1975–2013, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
        National Cancer Institute Bethesda, MD2016 ([http://seer.cancer.gov/csr/1975_2013/])
        • Health and Social Care Information Centre
        National Bowel Cancer Audit Progess Report.
        in: Tripartite colorectal meeting, Birmingham July 2014. 2014 ([http://www.tripartite2014.org/content/uploads/2013/05/NBOCAP-2014-Progress-Report.pdf])
        • Sorbye H.
        • Pfeiffer P.
        • Cavalli-Bjorkman N.
        • Qvortrup C.
        • Holsen M.H.
        • Wentzel-Larsen T.
        • et al.
        Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
        Cancer. 2009; 115: 4679-4687
        • Papamichael D.
        • Audisio R.
        • Horiot J.C.
        • Glimelius B.
        • Sastre J.
        • Mitry E.
        • et al.
        Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.
        Ann Oncol. 2009; 20: 5-16
        • Papamichael D.
        • Audisio R.A.
        • Glimelius B.
        • de Gramont A.
        • Glynne-Jones R.
        • Haller D.
        • et al.
        Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.
        Ann Oncol. 2014; 26: 463-476
        • Van Cutsem E.
        • Cervantes A.
        • Adam R.
        • Sobrero A.
        • Van Krieken J.H.
        • Aderka D.
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 1386-1422
        • Van Cutsem E.
        • Nordlinger B.
        • Cervantes A.
        Advanced colorectal cancer: ESMO clinical practice guidelines for treatment.
        Ann Oncol. 2010; 21: v93-7
        • Aparicio T.
        • Desrame J.
        • Lecomte T.
        • Mitry E.
        • Belloc J.
        • Etienney I.
        • et al.
        Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
        Br J Cancer. 2003; 89: 1439-1444
        • Beretta G.
        • Bollina R.
        • Cozzi C.
        Should we consider the weekly (w) chemotherapy (CT) with fluorouracil (F)+racemin folinic acid (f) a standard treatment for advanced/metastatic carcinoma of the digestive tract (DTC) in elderly patients (pts)?.
        Proc Am Soc Clin Oncol. 1997; 16 ([Abstract 920]): 259a
        • Folprecht G.
        • Cunningham D.
        • Ross P.
        • Glimelius B.
        • Di Costanzo F.
        • Wils J.
        • et al.
        Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
        Ann Oncol. 2004; 15: 1330-1338
        • Folprecht G.
        • Seymour M.
        • Saltz L.B.
        • Douillard J.Y.
        • Hecker H.
        • Stephens R.J.
        • et al.
        Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer. Combined analysis of 2,691 patients in randomized controlled trials.
        J Clin Oncol. 2008; 26: 1443-1451
        • Goldberg R.M.
        • Tabah-Fisch I.
        • Bleiberg H.
        • de Gramont A.
        • Tournigand C.
        • Andre T.
        • et al.
        Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
        J Clin Oncol. 2006; 24: 4085-4091
        • Aparicio T.
        • Jouve J.L.
        • Teillet L.
        • Gargot D.
        • Subtil F.
        • Le Brun-Ly V.
        • et al.
        Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
        J Clin Oncol. 2013; 31: 1464-1470
        • Seymour M.T.
        • Thompson L.C.
        • Wasan H.S.
        • Middleton G.
        • Brewster A.E.
        • Shepherd S.F.
        • et al.
        Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
        Lancet. 2011; 377: 1749-1759
        • Hurria A.
        • Togawa K.
        • Mohile S.G.
        • Owusu C.
        • Klepin H.D.
        • Gross C.P.
        • et al.
        Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
        J Clin Oncol. 2011; 29: 3457-3465
        • Giantonio B.J.
        • Catalano P.J.
        • Meropol N.J.
        • O'Dwyer P.J.
        • Mitchell E.P.
        • Alberts S.R.
        • et al.
        Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200.
        J Clin Oncol. 2007; 25: 1539-1544
        • Hurwitz H.
        • Fehrenbacher L.
        • Novotny W.
        • Cartwright T.
        • Hainsworth J.
        • Heim W.
        • et al.
        Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
        N Engl J Med. 2004; 350: 2335-2342
        • Saltz L.B.
        • Clarke S.
        • Diaz-Rubio E.
        • Scheithauer W.
        • Figer A.
        • Wong R.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Cassidy J.
        • Saltz L.B.
        • Giantonio B.J.
        • Kabbinavar F.F.
        • Hurwitz H.I.
        • Rohr U.P.
        Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
        J Cancer Res Clin Oncol. 2010; 136: 737-743
        • Hurwitz H.I.
        • Tebbutt N.C.
        • Kabbinavar F.
        • Giantonio B.J.
        • Guan Z.Z.
        • Mitchell L.
        • et al.
        Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
        Oncologist. 2013; 18: 1004-1012
        • Van Cutsem E.
        • Tabernero J.
        • Lakomy R.
        • Prenen H.
        • Prausova J.
        • Macarulla T.
        • et al.
        Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
        J Clin Oncol. 2012; 30: 3499-3506
        • Tabernero J.
        • Van Cutsem E.
        • Lakomy R.
        • Prausova J.
        • Ruff P.
        • van Hazel G.A.
        • et al.
        Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial.
        Eur J Cancer. 2014; 50: 320-331
        • Van Cutsem E.
        • Joulain F.
        • Hoff P.M.
        • Mitchell E.
        • Ruff P.
        • Lakomy R.
        • et al.
        Aflibercept plus FOLFIRI vs. placebo plus FOLFIRI in second-line metastatic colorectal cancer: a post hoc analysis of survival from the phase III VELOUR study subsequent to exclusion of patients who had recurrence during or within 6 months of completing adjuvant oxaliplatin-based therapy.
        Target Oncol. 2016; 11: 383-400
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Ruff P.
        • Ferry D.R.
        • Lakomy R.
        • Prausova J.
        • Van Hazel G.A.
        • Hoff P.M.
        • et al.
        Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
        Eur J Cancer. 2015; 51: 18-26
        • Bordonaro R.
        • Sobrero A.
        • Frassineti L.
        • Ciuffreda L.
        • Aprile G.
        • Thomas A.L.
        • et al.
        Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): interim safety data from the global aflibercept safety and quality-of-life program (ASQoP amd AFEQT studies) in patients ≥65.
        J Clin Oncol. 2014; 32 ([Abstract 545])
        • Bordonaro R.
        • Frassineti L.
        • Ciuffreda L.
        • Aprile G.
        • Thomas A.
        • Vishwanath R.
        • et al.
        Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): interim safety data from the global aflibercept safety and quality-of-life program (ASQoP amd AFEQT studies) in patients aged 65 or older.
        J Clin Oncol. 2015; 33 ([Abstract 588])
        • Ruff P.
        • Ferry D.
        • Papamichael D.
        • Lakomy R.
        • Prausova J.
        • Van Hazel G.
        • et al.
        Observed benefit of aflibercept in mCRC patients ≥65 years old: results of a prespecified age-based analysis of the VELOUR study.
        Ann Oncol. 2013; 24 ([abstract O-0017]): iv18
      1. Zaltrap full prescribing information.
        • Thai H.T.
        • Veyrat-Follet C.
        • Mentre F.
        • Comets E.
        Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
        Cancer Chemother Pharmacol. 2013; 72: 167-180